Market Overview - The Hong Kong stock market continued its rebound, with the Hang Seng Index rising 2.7% to 21,980 points last week, although it did not stabilize above the 22,000-point mark. The average daily trading volume increased to HKD 238.9 billion, indicating a recovery in capital activity [1] - The Hang Seng Tech Index only increased by 2.0% and failed to break the psychological barrier of 5,000 points, reflecting insufficient recovery momentum in the technology sector [1] - The healthcare and information technology sectors saw significant gains of 8.4% and 6.0%, respectively, while essential consumer goods and telecommunications sectors declined, indicating a rebalancing of funds between policy expectations and risk aversion [1] Economic Policy Insights - The April Politburo meeting maintained policy consistency, emphasizing that "early policy implementation leads to early effects," including accelerated issuance of special bonds and the implementation of long-term special government bonds [2] - The market outlook will depend on two key variables: progress in US-China tariff negotiations and the pace of domestic special bond issuance along with adjustments in real estate policies [2] Industry Dynamics - The Hang Seng Healthcare Index surged 8.9%, significantly outperforming the Hang Seng Index, driven by innovative pharmaceutical companies such as Kangfang (9926 HK), Xinda (1801 HK), and Rongchang (9995 HK) [3] - Kangfang Biotech's (9926 HK) drug, Idataf, received approval for a broader indication in treating non-small cell lung cancer, which is expected to positively impact sales [3] - Rongchang Biotech (9995 HK) reported a good operational performance in Q1, with expectations of a reduction in sales expense ratio by 2025 and a decrease in net losses for shareholders [3] Strategic Recommendations - The report suggests focusing on defensive sectors and policy catalysts, including high-dividend assets from state-owned enterprises, infrastructure-related sectors, and essential consumer goods benefiting from policy stimuli [12] - Monthly stock recommendations include Alibaba-W (9988 HK), China Resources Beverage (2460 HK), and others, indicating a focus on companies with stable earnings and growth potential [12]

Core Viewpoint - 康方生物's drug Ivosidenib has shown strong positive results in head-to-head clinical trials against other leading PD-1 inhibitors, raising expectations for the company's financial recovery and market position [1][2][3]. Group 1: Clinical Trial Results - Ivosidenib (PD-1/VEGF dual antibody) demonstrated significant improvement in progression-free survival (PFS) compared to Tislelizumab in a Phase III head-to-head trial for advanced squamous non-small cell lung cancer (sq-NSCLC) [1][2]. - The trial involved 532 participants from 66 clinical research centers, with Ivosidenib showing clinically meaningful PFS benefits in both PD-L1 positive and negative populations [2]. - Ivosidenib previously outperformed Pembrolizumab (Keytruda) in a separate Phase III trial, achieving an objective response rate (ORR) of 50% compared to 38.5% for Keytruda, and a disease control rate (DCR) of 89.9% versus 70.5% [3]. Group 2: Financial Performance - 康方生物 reported a revenue of 4.526 billion yuan in 2023, achieving its first annual profit, but faced a loss of 501 million yuan in 2024 despite generating 2.124 billion yuan in revenue [4]. - The company's financial performance is closely tied to Ivosidenib's sales, which generated 103 million yuan in revenue shortly after its market approval in May 2024 [4]. Group 3: Future Prospects - Ivosidenib is currently involved in 12 ongoing Phase III clinical trials, with one indication in the final review stage for supplemental new drug application [5]. - Goldman Sachs predicts that Ivosidenib could become a leader in the PD-1/L1×VEGF dual-specific antibody market, potentially reaching peak sales of 53 billion dollars by 2041 [5]. - 康方生物 also has other products in its pipeline, including a PD-1/CTLA-4 dual antibody and a recently FDA-approved drug for nasopharyngeal carcinoma [5].